Latest News

Manchester, UK – July 1, 2026 – Axalbion Therapeutics Limited, a clinical-stage biopharmaceutical company developing novel medicines for the treatment of chronic cough, today announced the appointment of Stephanie Read as Chief Executive Officer and Director.

Manchester, UK and Mountain View, Calif, August 27, 2024 – Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, announced that the first patient has been dosed in the second part of a Phase 2 proof-of-concept, randomized, placebo-controlled clinical study in chronic cough with AX-8, its lead compound. AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel. The company has raised additional financing from existing and new investors to support the trial execution and Phase 3 planning.

Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort